Amy S. Clark

Also affiliated with Hospital of the University of Pennsylvania, University of Pennsylvania

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 22 papers. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2022.7949

N/A

1.4DataRank · unranked

52 citations

Vera J. Suman, Antonino B. D’Assoro, Jodi M. Carter, Karthik V. Giridhar, Brendan P. McMenomy +18 more

In vivo visualization of PARP inhibitor pharmacodynamics

JCI Insight(2021)10.1172/jci.insight.146592

N/A

1.1DataRank · unranked

32 citations

Austin R. Pantel, Payal D. Shah, Michael D. Farwell, Amy S. Clark, Robert K. Doot +3 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07636-3

N/A

0.208DataRank · unranked

3 citations

Rebecca A. Hubbard, Amanda M. Smith, Kyunga Ko, Anran Huang, Jessica Wang +18 more

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.46201

N/A

0.208DataRank · unranked

3 citations

Amanda M. Smith, Bénédicte Lefebvre, Faizi Jamal, Saro H. Armenian, Daniel Koropeckyj-Cox +21 more

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

JAMA Oncology(2023)10.1001/jamaoncol.2022.7770

N/A

0DataRank · unranked

25 citations

Rebecca A. Hubbard, Erkuan Wang, Trevor J. Royce, Aaron B. Cohen, Amy S. Clark +2 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1572

N/A

0DataRank · unranked

1 citations

Teresa Helsten, Brian Moore, Linda Neuhauser, Barbara LeStage, Paolo Castillo +12 more

Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy

JACC CardioOncology(2025)10.1016/j.jaccao.2025.01.012

N/A

0DataRank · unranked

12 citations

Kyunga Ko, Lin Ma, Ian Messing, Casey Hollawell, Amanda M. Smith +19 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer

npj Breast Cancer(2025)10.1038/s41523-025-00853-5

N/A

0DataRank · unranked

0 citations

Tien-Chi Pan, Dhruv K. Pant, Yan Chen, George W. Woodfield, Jewell Graves +31 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0DataRank · unranked

447 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0DataRank · unranked

335 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0DataRank · unranked

73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab

JACC Basic to Translational Science(2021)10.1016/j.jacbts.2021.10.010

N/A

0DataRank · unranked

14 citations

Biniyam G. Demissei, Amanda M. Smith, Priya Brahmbhatt, Jessica Wang, Amy S. Clark +10 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more